1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
    + Filter
    Loading...
    Custom Services order now ship next day

    DLL3

    Loading...

    Anti-DLL3 Products

    More Infomation

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Creative Biolabs provides top-tier, cutting-edge anti-DLL3 antibodies to researchers worldwide. With a focus on enhancing the understanding of DLL3, a key target in several diseases, we strive to meet the diverse needs of the scientific community. Our innovative products are designed to support your research, helping drive progress in the field and enabling researchers to make meaningful discoveries.

    DLL3: A Crucial target in Cancer Diseases

    DLL3 (delta-like ligand 3) is a pivotal protein that plays an essential role in various cellular signaling pathways critical for development, differentiation, and cellular function. Its dysregulation has been implicated in numerous diseases, especially specific cancers. Studying DLL3 is vital for uncovering the mechanisms driving these conditions. Gaining a deeper understanding of DLL3's interactions and functions can lead to the creation of targeted therapies that specifically address its abnormal activity, offering more effective treatment options for patients. Additionally, research on DLL3 provides valuable insights into core biological processes and may lead to the development of new diagnostic tools.

    Alternative Names

    Delta like canonical Notch ligand 3; SCDO1

    Background

    This gene encodes a member of the delta protein-ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Mutations in this gene cause autosomal recessive spondylocostal dysostosis 1. Two transcript variants encoding distinct isoforms have been identified for this gene.

    Protein class

    Disease related genes, Human disease related genes, Plasma proteins

    Predicted location

    Intracellular, Membrane (different isoforms)

    Single cell type specificity

    Group enriched (Spermatogonia, Oligodendrocyte precursor cells)

    Immune cell specificity

    Immune cell enhanced (memory B-cell, naive CD8 T-cell)

    Cell line specificity

    Cell line enriched (SK-MEL-30)

    Interaction

    Can bind and activate Notch-1 or another Notch receptor.

    Molecular function

    Developmental protein

    More Types Infomation

    Anti-DLL3 rAb Products

    Our commitment is to deliver top-quality anti-DLL3 recombinant antibodies to support and enhance research focused on the DLL3 target. These reliable products are crafted to accelerate scientific exploration, helping to drive progress and deepen understanding in this area of study.

    Cat. No. Product Name Target Species Host Species Applications
    HPAB-2178LY Mouse Anti-DLL3 Recombinant Antibody Human Mouse ELISA; FC
    HPAB-2095LY Mouse Anti-DLL3 Recombinant Antibody Human Mouse ELISA; FC
    HPAB-2174LY Mouse Anti-DLL3 Recombinant Antibody Human Mouse ELISA; FC
    HPAB-2183LY Mouse Anti-DLL3 Recombinant Antibody Human Mouse ELISA; FC
    HPAB-2189LY Human Anti-DLL3 Recombinant Antibody Human Human ELISA; FC

    Customer Reviews

    Excellent
    Q**nn
    Mouse Anti-DLL3 Recombinant Antibody (Cat#: HPAB-2178LY)
    For my research, I selected the mouse anti-DLL3 recombinant antibody to examine DLL3 expression in various cell types and tissues. Using ELISA and flow cytometry, the antibody demonstrated excellent specificity and sensitivity. In ELISA assays, it accurately quantified DLL3 levels, while flow cytometry effectively identified DLL3-expressing cells. The results were both reliable and instrumental in advancing my research.
    23/Oct/2020
    Excellent
    Si**na
    Human Anti-DLL3 Recombinant Antibody (Cat#: HPAB-2189LY)
    I acquired the human anti-DLL3 recombinant antibody for my biomedical research. It was utilized in immunohistochemistry and Western blotting on tumor samples, where it exhibited excellent specificity and sensitivity in detecting DLL3. The results were consistent and reproducible, offering valuable insights. This antibody has proven to be a dependable resource for my research.
    19/Nov/2021

    rAb Production

    With years of extensive experience in recombinant antibody production and optimization, Creative Biolabs is committed to delivering top-quality products. Our skilled team focuses on maintaining high standards of excellence in every stage of production. By leveraging advanced techniques and efficient processes, we ensure that our recombinant antibodies are available promptly, supporting your research and applications with superior service and reliability.

    Featured Anti-DLL3 Recombinant Antibody Production PlatformsFig.1 Anti-DLL3 recombinant antibody production: milligram-scale. (Creative Biolabs Original)
    Fig.1 Milligram-scale recombinant antibody production.

    Fig.2 Anti-DLL3 recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.2 Gram-scale recombinant antibody production.

    rAb Modalities

    Creative Biolabs offers a wide range of high-quality antibody formats to cater to the varied needs of our customers. These formats include full-length, scFab, scFv-Fc, Fc fusion, and more. With our extensive expertise in antibody production, we guarantee superior quality and performance for diverse applications.

    Fig.3 Diverse anti-DLL3 recombinant antibody production and modalities. (Creative Biolabs Original)Fig.3 Diverse anti-DLL3 recombinant antibody production and modalities.

    Drug Information Targeting DLL3

    Table 1. Therapeutic approaches targeting DLL3 in clinical development.

    Research phase Company Classification Indications Details
    Registered - 2024 Amgen Biologics Cancer This is a bispecific T-cell engager antibody targeting the delta-like ligand 3 (DLL3) and CD3 being developed by Amgen.
    Phase II Boehringer Ingelheim Biologics Cancer It is a T-cell-engaging bispecific antibody targeting CD3 and the delta-like ligand 3 (DLL3) being developed by Boehringer Ingelheim for the treatment of various subtypes of DLL3-expressing cancers.
    Phase I/II Harpoon Therapeutics Biologics Cancer This is a delta like ligand 3- (DLL3) targeting tri-specific T cell activating construct (TriTAC(R)) in early clinical development at Harpoon Therapeutics (now part of Merck & Co) as monotherapy and in combination with atezolizumab in patients with relapsed or refractory DLL3-expressing small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC) and other high-grade neuroendocrine tumor types other than SCLC and NEPC.
    Phase I Shanghai Simnova Biotechnology Biologics Cancer It is a cell therapy consisting of T lymphocytes expressing a chimeric antigen receptor (CAR) targeting delta-like ligand 3 (DLL3), is in early clinical development at Shanghai Simnova Biotechnology for the treatment of recurrent/refractory small cell lung cancer and lung large cell neuroendocrine carcinoma.
    Phase I MediLink Therapeutics Drug Conjugates Cancer This is an antibody-drug conjugate (ADC) targeting DLL3 in the early clinical development stage at Zai Lab as a treatment for metastatic or extensive-stage small cell lung cancer (SCLC), a subtype of cancer known to overexpress DLL3.
    Phase I Chugai Pharmaceutical Biologics Cancer It is a T-cell redirecting antibody targeting CD3 and CD137 using Chugai's Dual-Ig technology in early clinical development at Roche and Chugai Pharmaceuticals for the intravenous treatment of advanced extensive-stage small-cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas.
    Phase I Legend Biotech Biologics Cancer This is a CAR T-cell therapy consisting of human autologous T-cells expressing a CAR targeting the delta-like ligand 3 (DLL-3) in early clinical development at Legend Biotech for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and large cell neuroendocrine carcinoma (LCNEC).
    Phase I Qilu Pharmaceutical Biologics Cancer It is a bispecific humanized antibody targeting the delta-like ligand 3 (DLL-3) and CD3 and acting as a T-cell engager through CD3, being developed by Qilu Pharmaceutical as an intravenous treatment for DLL-3-expressing solid tumors.
    Phase I Phanes Therapeutics Biologics Cancer This is a bispecific antibody against DLL3 and CD47, thereby capable of polarizing tumor-associated macrophages, being developed by Phanes Therapeutics as an intravenous immunotherapeutic for DLL3-expressing solid tumors.
    Phase I Amgen Biologics Cancer It is a chimeric antigen receptor T-cell (CAR-T) therapy targeting delta-like protein 3 (DLL3) in developments at Amgen.

    If you're interested in learning more about our anti-DLL3 recombinant antibody products, please don't hesitate to contact us anytime. Our dedicated team is ready to assist you with any questions you might have. We look forward to supporting your research and providing you with the information you need.

    Go to compare

    Go to compare